Physician
Oncology
Dr. Evanthia Galanis, MD
|
|
Give Review
Evanthia Galanis is an expert in the field of Oncology. She received awards:"Elected Member", "Award of Excellence", "AACR/Glaxo Wellcome Award", "Outstanding Achievement Award in Oncology", "Award on Genetics in Oncology", "Award on Clinical Pharmacology of Anticancer Drugs", "Linse-Bock Fellowship in Neuro-Oncology", "AACR Scholarship", "Award on Epidemiology and Clinical Trial Design", "Internal Medicine Outstanding Research Award", "Valedictorian", "Scholarship for Completion of D.Sc Thesis" and "Yearly Scholarships". Evanthia Galanis is a published doctor. She published 26 publications, including: 'What next for newly diagnosed glioblastoma?' Evanthia Galanis is registered with Medicare.
Publications
- The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
- What next for newly diagnosed glioblastoma?
- Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
- Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian Cancer.
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
- Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.
- Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24-/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative Breast can...
- Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group.
- Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy.
- New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled Analysis of EORTC/RTOG/NC...
- Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial.
- Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
- Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.
- Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast Cancer cells.
- Incorporation of prognostic and predictive factors into glioma clinical trials.
- Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian Cancer.
- Oncolytic measles virus strains as novel antiCancer agents.
- The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ER?(+) breast Cancer cells.
- Phase II Trial of Intravenous Administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma.
- Attenuated oncolytic measles virus strains as Cancer therapeutics.
- Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central Cancer treatment group study.
- Bioluminescent imaging of intracranial vestibular Schwannoma xenografts in NOD/SCID mice.
- Engineered measles virus as a novel oncolytic therapy against prostate Cancer.
- Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells.
Schools
University Of Athens School Of Health Sciences
Mayo Med School
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
- Award of Excellence
- AACR/Glaxo Wellcome Award
- Outstanding Achievement Award in Oncology
- Award on Genetics in Oncology
- Award on Clinical Pharmacology of Anticancer Drugs
- Linse-Bock Fellowship in Neuro-Oncology
- AACR Scholarship
- Award on Epidemiology and Clinical Trial Design
- Internal Medicine Outstanding Research Award
- Valedictorian
- Scholarship for Completion of D.Sc Thesis
- Yearly Scholarships
Education
-
Mayo School of Graduate Medical Education -
University of Athens
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1326028234 | |
| NPPES Provider LastName | GALANIS | |
| NPPES Provider FirstName | EVANTHIA | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 14.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326028234 |
| Last Name Of The Provider | GALANIS |
| First Name Of The Provider | EVANTHIA |
| View All |
Similar Doctors
|
|
Dr. Janell N. Shaw, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles L. Loprinzi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Aminah Jatoi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick A. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul Haluska Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward T. Creagan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sani H. Kizilbash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen Frytak, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Joseph Rubin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James N. Ingle, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Timothy J. Hobday, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Paul D. Brown, MD |
|
|
Dr. Frank A. Sinicrope, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|